Prognostic Significance of Adipose Tissue Distribution and Metabolic Activity in PET/CT in Patients with Metastatic Colorectal Cancer

Basit Öğe Kaydı
dc.contributor.authorKaracelik, Tuba
dc.contributor.authorKaya, Bugra
dc.contributor.authorKorkmaz, Mustafa
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorAraz, Murat
dc.contributor.authorEryilmaz, Melek Karakurt
dc.contributor.authorBozcuk, Hakan Sat
dc.date.accessioned2024-02-23T13:59:46Z
dc.date.available2024-02-23T13:59:46Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractPurpose In this study, we aimed to evaluate the prognostic significance of adipose tissue distribution and metabolic activity in PET/CT to predict survival in patients with metastatic colorectal cancer (mCRC). Methods The volume, density (HU), and FDG uptake (standardized uptake value (SUV)) of visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) and maximum FDG uptake of the tumor tissue were measured. Subcutaneous adipose tissue of volume-to-density ratio (SAT ratio) was calculated. Results The median OS for the patients with SAT ratio value < -1.1 and >= -1.1 were 38.5 (95% CI 31.54-45.58) and 24.5 (95% CI 14.13-34.93) months, respectively (p = 0.05). During follow-up, 69 patients experienced disease progression. The median progression-free survival (PFS) was 11.03 months (95% CI: 9.11-12.95). Median PFS for patients with tumor SUV max value < 11.5 and >= 11.5 were 9.2 (95% CI 7.25-11.27) and 12.6 (95% CI 10.02-15.27) months, respectively (p = 0.14). Forty-eight patients received bevacizumab therapy. VAT SUV mean (HR: 0.09; 95% CI 0.01-0.52, p = 0.008) was significantly associated with PFS in patients receiving bevacizumab. SAT ratio was the significant parameter for the OS (HR: 0.58; 95% CI 0.33-1.01, p = 0.05) and PFS (HR: 1.99; 95% CI 1.02-3.91, p = 0.043). Conclusions SAT ratio was an independent prognostic factor for survival in patients with mCRC. Higher SAT volume is correlated with longer survival in mCRC patients.en_US
dc.identifier.doi10.1007/s12029-022-00819-x
dc.identifier.endpage466en_US
dc.identifier.issn1941-6628
dc.identifier.issn1941-6636
dc.identifier.issue2en_US
dc.identifier.pmid35404000en_US
dc.identifier.scopus2-s2.0-85127943792en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage456en_US
dc.identifier.urihttps://doi.org/10.1007/s12029-022-00819-x
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11318
dc.identifier.volume54en_US
dc.identifier.wosWOS:000780837200002en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal Of Gastrointestinal Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdipose Tissueen_US
dc.subjectColorectal Canceren_US
dc.subjectFdg Peten_US
dc.subjectCten_US
dc.subjectPrognosisen_US
dc.titlePrognostic Significance of Adipose Tissue Distribution and Metabolic Activity in PET/CT in Patients with Metastatic Colorectal Canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu